Topics

Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter

18:25 EST 3 Feb 2020 | SCRIP

Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.

      

Related Stories

 

Original Article: Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter

NEXT ARTICLE

More From BioPortfolio on "Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter"

Quick Search

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...